Your session is about to expire
← Back to Search
Nebulized vs. IV Ketamine for Pain
Study Summary
This trial will help to establish the most efficacious route and dose of ketamine for acute pain management in the ED.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have both short-term and long-term painful conditions.Patients with erectile dysfunction.You are experiencing changes in your thinking, behavior or mood.You have a history of alcohol or drug abuse or have been diagnosed with schizophrenia.You are experiencing moderate to severe pain, rated as 5 or higher on a scale of 0 to 10.
- Group 1: IV SDK
- Group 2: K-BAN
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 5 Other Conditions - This treatment demonstrated efficacy for 5 other conditions.
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are recruitments currently underway for this research project?
"Confirmed. According to clinicaltrials.gov, the trial was initiated on October 4th 2021 and has been actively recruiting since then - with a most recent update of October 19th 2022. This medical study will require 150 participants at one location."
Has K-BAN received the green light from regulatory bodies?
"As this is a Phase 4 drug trial, the safety of K-BAN has been confirmed and thus it receives a score of 3 on our team's scale."
For what demographic is enrollment in this trial open?
"This clinical trial is seeking 150 individuals aged 18-120 suffering from pain. Applicants must be awake, oriented to their person, place and time, able to communicate any adverse effects they experience and measure the severity of their symptoms via a 0-10 numerical rating scale (NRS), with 5 or more as an indicator for eligibility. Furthermore, acute and chronic painful conditions in both emergency department patients are being considered."
Is the current research endeavor accepting participants aged eighty-five and above?
"This medical trial requires subjects to be between 18 and 120 years of age. Those who don't meet this criteria may find there are 83 other studies available for minors, or 329 research initiatives suitable for seniors."
What is the aggregate number of individuals signing up for this research project?
"Affirmative. Evidence hosted on clinicaltrials.gov indicates that this medical trial, whose commencement was October 4th of 2021, is still recruiting participants. Specifically, the research team needs to find 150 people at one site to join their study."
Share this study with friends
Copy Link
Messenger